よむ、つかう、まなぶ。
05 参考資料１－２ 13価肺炎球菌コンジュゲートワクチン（成人用）ファクトシート (23 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_36630.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第22回 12／1）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated
nursing home residents. N Engl J Med. 338:1861-1868,1998.
25．Kuroki T, Ishida M, Suzuki M, Furukawa I, Ohya H, Watanabe Y, et al. Outbreak of
Streptococcus pneumoniae serotype 3 pneumonia in extremely elderly people in a
nursing home unit in Kanagawa, Japan, 2013. Am J Geriatric Soc 62: 1197-1198,2014.
26．常
金
彬、他. 成人の重症肺炎サーベイランス構築に関する研究（厚生労働科学研究費補助
新型インフルエンザ等新興・再興感染症研究事業
研究代表者：大石和徳）平成 26
年度総括・分担研究報告書 p63-67. 2015 年 3 月
27．Chiba N, Morozumi M, Sunaoshi K, Takahashi S, Takano M, Komori T, et al. Serotype
and antibiotic resistance of isolates from patients with invasive pneumococcal
diseases in Japan. Epidemiol Infect 138:61-68,2010
28．Isozumi R, Ito Y, Ishida T, Osawa M, Hirai T, Ito I, et al. Genotypes and related
factors reflecting macrolide resistance in pneumococcal pneumonia infections in
Japan. J Clin Microbiol. 45:1440-1446, 2007
29．Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, et al.
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared
to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive
adults. Vaccine. 31:3577-3584, 2013.
30．Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, et al.
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults
70 years of age and older previously vaccinated with 23-valent pneumococcal
polysaccharide vaccine. Vaccine. 31:3585-3593, 2013.
31．Namkoong H, Funatsu Y, Oishi K, Akeda Y, Hiraoka R, Takeshita K, et al. Comparison
of the immunogenicity and safety between polysaccharide and protein-conjugated
pneumococcal vaccines among the elderly aged 80 years or older in Japan: An
open-labeled randomized study. Vaccine 33:327-332, 2015.
32．Shiramoto M, Irie S, Juergens C, Yamaji M, Tamai S, Aizawa M, et al. Immunogenicity
and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy
Japanese adults aged ≥50 years An open-label trial. Hum Vaccin Immunother.
10:1850-1858,2014
33．Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, et al. Sequential
administration
of
13-valent
pneumococcal
conjugate
vaccine
and
23-valent
pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64
years of age. Vaccine. 32:2364-2374, 2014.
34．Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, et al. Influence
of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent
23
nursing home residents. N Engl J Med. 338:1861-1868,1998.
25．Kuroki T, Ishida M, Suzuki M, Furukawa I, Ohya H, Watanabe Y, et al. Outbreak of
Streptococcus pneumoniae serotype 3 pneumonia in extremely elderly people in a
nursing home unit in Kanagawa, Japan, 2013. Am J Geriatric Soc 62: 1197-1198,2014.
26．常
金
彬、他. 成人の重症肺炎サーベイランス構築に関する研究（厚生労働科学研究費補助
新型インフルエンザ等新興・再興感染症研究事業
研究代表者：大石和徳）平成 26
年度総括・分担研究報告書 p63-67. 2015 年 3 月
27．Chiba N, Morozumi M, Sunaoshi K, Takahashi S, Takano M, Komori T, et al. Serotype
and antibiotic resistance of isolates from patients with invasive pneumococcal
diseases in Japan. Epidemiol Infect 138:61-68,2010
28．Isozumi R, Ito Y, Ishida T, Osawa M, Hirai T, Ito I, et al. Genotypes and related
factors reflecting macrolide resistance in pneumococcal pneumonia infections in
Japan. J Clin Microbiol. 45:1440-1446, 2007
29．Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, et al.
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared
to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive
adults. Vaccine. 31:3577-3584, 2013.
30．Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, et al.
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults
70 years of age and older previously vaccinated with 23-valent pneumococcal
polysaccharide vaccine. Vaccine. 31:3585-3593, 2013.
31．Namkoong H, Funatsu Y, Oishi K, Akeda Y, Hiraoka R, Takeshita K, et al. Comparison
of the immunogenicity and safety between polysaccharide and protein-conjugated
pneumococcal vaccines among the elderly aged 80 years or older in Japan: An
open-labeled randomized study. Vaccine 33:327-332, 2015.
32．Shiramoto M, Irie S, Juergens C, Yamaji M, Tamai S, Aizawa M, et al. Immunogenicity
and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy
Japanese adults aged ≥50 years An open-label trial. Hum Vaccin Immunother.
10:1850-1858,2014
33．Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, et al. Sequential
administration
of
13-valent
pneumococcal
conjugate
vaccine
and
23-valent
pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64
years of age. Vaccine. 32:2364-2374, 2014.
34．Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, et al. Influence
of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent
23